FDA approves brolucizumab-dbll 6 mg for the treatment of DME - Ophthalmology Times
6/1/2022 12:00:00 AM2 years 11 months ago
by David Hutton, OT Staff Reports
by David Hutton, OT Staff Reports
According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular edema patients.
Novartis today announced that the FDA has approved brolucizumab-dbll 6 mg (BEOVU) for the treatment of diabetic macular edema (DME). According to the company, the approval represents the second FDA-… [+6156 chars]
full article...